Email Subscribe
Next Generation Gene Therapy Vectors Summit 2023
Time: Tuesday, June 27, 2023 – Thursday, June 29, 2023
Address: Hilton Boston Back Bay, 40 Dalton St, Boston, MA 02115, USA
Contact: Irene Song(Sr. Director, Global Product)


The gene therapy industry has continued to rapidly expand over the last year as exciting new platforms are emerging onto the space, while existing players look to advance to the next generation. Leaps and bounds have been made towards better and safer vectors in response to safety and toxicity concerns.

During this IP explosion, the 3rd Next Generation Gene Therapy Vectors Summit is set to bring together key leaders in a highly technical setting to decide the future of the industry. Shifting focus from last year, we are featuring a deeper dive into AAV vector design and the next generation vector systems competing with it.

Hear from experts across 3 days of technical panel discussions, platform showcases, case studies and seminars. Upgrade to the next generation with the only summit aimed at improving the safety, toxicity, specificity, and scalability of the current generation of gene therapy vectors.

ASGCT 26th Annual Meeting (Los Angeles, May 16-20)
Current Challenges and Our Approaches to Developing Best-in-Class rAAV Manufacturing Processes for Large-scale GMP production.
Time: May 18, Thursday, 2:30pm-3:00pm
Address: Room 511 Exhibitor Showcase, visit us at booth 462
Speaker: Dr. Berenice Carrillo, Associate Director, Downstream Process & Analytical Development

Dr. Berenice Carrillo
Adeno-associated virus (AAV) vectors stand as one of the most popular technologies for gene therapy, merited to its lack of immunogenicity and pathogenicity in humas, low risk of insertional mutagenesis, long-term transgene expression, and broad range of infectivity. Although rAAV was initially used for the treatment of ultrarare conditions, it is now being used to treat a variety of diseases, thus increasing the demand for large-scale production of rAAV. This presents a challenge as these broader rAAV therapies require higher yields. Here we present the approaches that PackGene has undertaken to increase rAAV productivity and product quality attributes. With the use of PackGene’s proprietary π-Alpha™ 293 AAV High-yield Platform, and in combination with in-process upstream and downstream QbD optimization of media and feed, we observed an increase in rAAV production by 3 to 8 times in various AAV serotypes. Additionally, a reduction in empty capsid, residual plasmid and host cell DNA was also achieved with improved biological function.